• Home
• Partneringtools
• Reports

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Consulting
• Jobs
• Forums

• About us
• Products
• Newsletter

Pharmalicensing Ltd
is a division of

— LONDONMarch 7

Cannabis-derived medicines may one day be used in the treatment of Alzheimer's disease which affects 417,000 people in the UK.

LONDON, March 7 /PRNewswire/ -- Cannabis-derived medicines may one day be used in the treatment of Alzheimer's disease which affects 417,000 people in the UK.

Professor Raphael Mechoulam of the Hebrew University of Jerusalem, Israel, will present new findings to a group of international experts at a Cannabinoids Medicines Symposium to be held at the Royal Pharmaceutical Society of Great Britain (RPSGB) in London on Monday, 10 March. The research, still at an early stage, indicates that memory loss, the main symptom of Alzheimer's, can be slowed down significantly in mice by some of the chemicals present in cannabis. The next step will be to initiate human trials to see if the same effect can be achieved on the human brain.

The research is promising for the millions of suffers of the disease and their carers. Alzheimer's disease is the commonest form of dementia, which affects an estimated 24.3 million people worldwide.

It is ten years since the RPSGB launched its protocols to demonstrate the therapeutic effectiveness of cannabis. These protocols led to the Government funded UK trials that looked at the medicinal benefits of cannabis for patients with multiple sclerosis and in the treatment of severe pain. Cannabis-derived medicines have subsequently entered the market and are currently available to patients in Canada.

Professor Tony Moffat, who is chairing the Symposium on Monday said: "We have come a long way in ten years and there is still a lot of research ground to cover. There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain. Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery."

Notes to editors

About Professor Mechoulam's research

The research was conducted by Professor Raphael Mechoulam of the Hebrew University of Jerusalem, Israel, and a team led by Dr Maria de Ceballos, Cajal Institute, Madrid. In the studies, mice were injected directly into the brain with a molecule found in the human brain of patients suffering from Alzheimer's disease, which is known to be responsible for memory loss. These animals were then treated over a week with cannabidiol. The animals were then assessed as to their learning ability measured by the time needed for them to find a hidden platform in a maze. Mice injected with cannabidiol found the platform within 25-30 seconds, compared to 45-55 seconds of those in a control group who had not been treated with cannabidiol.

UK statistics on Alzheimer's disease

- Alzheimer's disease is the most common form of dementia

- The disease affects around 417,000 people in the UK

Alzheimer's Society http://www.alzheimers.org.uk

Source: Worldwide Statistics on dementia

- Approximately 24.3 million people suffer with dementia

- 4.6 million new cases of dementia are reported every year which equates to one new case every 7 seconds

- The number of people affected with dementia will double every 20 years to 81-1 million by 2040

Source: The Lancet 2005; 366:2112-2117 http://www.thelancet.com/journals/lancet/article/PIIS0140673605678890

About Alzheimer's

People in the early stages of Alzheimer's disease may experience lapses of memory and have problems finding the right words. As the disease progresses they may:

- Become confused, and frequently forget the names of people, places, appointments and recent events

- Experience mood swings. They may feel sad or angry. They may feel scared and frustrated by their increasing memory loss

- Become more withdrawn due either to a loss of confidence or to communication problems

Source: Alzheimer's Society: http://www.alzheimers.org.uk

About the Royal Pharmaceutical Society of Great Britain (RPSGB)

The RPSGB is the professional and regulatory body for pharmacists in England, Scotland and Wales. It also regulates pharmacy technicians on a voluntary basis, which is expected to become statutory under anticipated legislation. The primary objectives of the Society are to lead, regulate, develop and represent the profession of pharmacy. For further information visit http://www.rpsgb.org.

Royal Pharmaceutical Society of GB

For media enquiries please contact the RPSGB's Public Relations Unit, Samuel Ridge - Tel: +44(0)20-7572-2653, email: Samuel.Ridge@rpsgb.org. For out of hours enquiries please call +44(0)7739-533658.

• Royal Pharmaceutical Society of Great Britain

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us